AKT1 E17K mutant phosphorylates p21Cip1 and p27Kip1

Stable Identifier
R-HSA-2399969
Type
Reaction
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
Summation

AKT1 E17K gain-of-function mutant preserves the ability to phosphorylate CDKN1B i.e. p27Kip1 (Malanga et al. 2008) and is expected to phosphorylate CDKN1A i.e. p21Cip1, like the wild-type AKT (Viglietto et al. 2002), although this has not been experimentally tested.

Literature References
PubMed ID Title Journal Year
12244303 Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer

Viglietto, G, Motti, ML, Bruni, P, Melillo, RM, D'Alessio, A, Califano, D, Vinci, F, Chiappetta, G, Tsichlis, P, Bellacosa, A, Fusco, A, Santoro, M

Nat Med 2002
18256540 Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung

Malanga, D, Scrima, M, De Marco, C, Fabiani, F, De Rosa, N, De Gisi, S, Malara, N, Savino, R, Rocco, G, Chiappetta, G, Franco, R, Tirino, V, Pirozzi, G, Viglietto, G

Cell Cycle 2008
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
protein serine/threonine kinase activity of p-T308,S473-AKT1 E17K [cytosol]
Physical Entity
Activity
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed